Bristol Myers Squibb Reports Seven-Year CheckMate-214 Data for Opdivo Plus Yervoy in RCC

Bristol Myers Squibb today presented seven-year overall survival data from the Phase 3 CheckMate-214 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated advanced renal cell carcinoma. The data showed that 39% of patients in the Opdivo plus Yervoy arm were alive at seven years compared to 32% in the sunitinib arm.